The purpose of this study is to determine the effects of daratumumab and lenalidomide without steroids for treating patients with multiple myeloma.

SparkCures ID	1131
Trial Phase	Phase 2
Enrollment	28 Patients
Treatments	Daratumumab Dexamethasone Lenalidomide
Tags	CD38 Monoclonal Antibody
Trial Sponsors	University of Rochester Medical Center Wilmot Cancer Center
NCT Identifier	NCT04635189

Am I Eligible?

The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.

The following criteria is provided for health care professionals.

Inclusion Criteria:

Diagnosis of multiple myeloma with diagnosis
Must not have received previous therapy for multiple myeloma
Newly diagnosed and not considered candidate for high-dose chemotherapy
Adequate organ system function
A performance status ≤ 3
Ability to swallow and retain oral medication
Female subjects of child bearing potential must be surgically sterile, be post-menopausal

Exclusion Criteria:

A diagnosis of primary amyloidosis; monoclonal gammopathy of undetermined significance, smoldering multiple myeloma; non-secretory myeloma
A diagnosis of Waldenström's disease
Receiving cancer therapy
Radiation therapy within 14 days of enrollment
Major surgery within 2 weeks before enrollment
Human immunodeficiency virus -infected patients must be on effective anti-retroviral therapy with undetectable viral load within the past 6 months
Seropositive for hepatitis B, or seropositive for hepatitis C
Ongoing systemic bacterial, fungal or viral infection
Severe and/or uncontrolled medical conditions
Malignancy within 2 years of study enrollment
Women who are pregnant or lactating
Contraindications to required prophylaxis for deep vein thrombosis and pulmonary embolism.

Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma

Overview

Am I Eligible?

US Trial Locations